

Anti-TNFRSF10B/TRAILR2/CD262 Antibody (Drozitumab)

Introduction

Drozitumab (PRO 95780) is a human agonist monoclonal antibody that binds to the death receptor DR5. Drozitumab has potent antitumor activity against rhabdomyosarcoma.

Product parameters

Alternative Names	RG-7425, RG7425
Target Accession	O14763
Target	TNFRSF10B / TRAILR2 / CD262
CAS number	912628-39-8
Molecular Weight	143.06 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized Cynomolgus TRAIL R2/DR5/ TNFRSF10B Protein, His Tag at 2 ug/mL can bind drozitumab, EC50=0.1257 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

